Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Buy” by Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been assigned an average rating of “Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $19.14.

A number of equities research analysts recently weighed in on REPL shares. BMO Capital Markets increased their price target on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Finally, HC Wainwright lifted their target price on shares of Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd.

Insider Buying and Selling at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC increased its stake in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares during the last quarter. Braidwell LP increased its stake in shares of Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after purchasing an additional 2,057,460 shares during the last quarter. State Street Corp raised its holdings in shares of Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after buying an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Replimune Group by 10.0% during the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after buying an additional 1,000,000 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its stake in Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after buying an additional 238,747 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Stock Down 3.2 %

Shares of REPL stock opened at $13.62 on Friday. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.00. The stock has a market cap of $931.88 million, a price-to-earnings ratio of -4.47 and a beta of 1.28. The firm’s 50-day moving average is $12.51 and its 200-day moving average is $11.45. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07. Sell-side analysts predict that Replimune Group will post -2.88 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.